Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease with high mortality.
Two novel antifibrotic agents, pirfenidone and nintedanib, have received licences for use in …

Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease of unknown
cause. Approximately 5,000 people are diagnosed with IPF in the UK every year. People …

Background Pirfenidone and nintedanib are the only disease-modifying treatments available
for idiopathic pulmonary fibrosis (IPF). Our aim was to test their effectiveness and safety in …

Idiopathic pulmonary fibrosis (IPF) is a fibrotic lung disease associated with significant
morbidity and mortality. Historically, IPF has been managed using combination …

Idiopathic pulmonary fibrosis (IPF) is a progressive disease with a dismal prognosis. The
average life expectancy of untreated patients with IPF is only 3 to 4 years. Decline in forced …

Abstract Background Research questions To compare the efficacy of nintedanib and
pirfenidone in the treatment of progressive pulmonary fibrosis; and to compare the efficacy of …

Recently, two drugs have been approved in a number of countries for the treatment of IPF.
Pirfenidone and nintedanib, the first antifibrotic pharmacological drugs to treat IPF, target …

Idiopathic pulmonary fibrosis (IPF) is a fatal progressive lung disease occurring in adults. In
the last decade, the results of a number of clinical trials based on the updated disease …

Currently many questions remain regarding the use of pirfenidone and nintedanib in IPF,
including which drug to prescribe, the optimal patient population to treat, the duration of …

Introduction Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and irreversible
lung disease. Licensed treatment options for IPF are pirfenidone and nintedanib. The aim of …